Literature DB >> 18930058

Membrane binding of oligomeric alpha-synuclein depends on bilayer charge and packing.

Bart D van Rooijen1, Mireille M A E Claessens, Vinod Subramaniam.   

Abstract

Membrane disruption by oligomeric alpha-synuclein (alphaS) is considered a likely mechanism of cytotoxicity in Parkinson's disease (PD). However, the mechanism of oligomer binding and the relation between binding and membrane disruption is not known. We have visualized alphaS oligomer-lipid binding by fluorescence microscopy and have measured membrane disruption using a dye release assay. The data reveal that oligomeric alphaS selectively binds to membranes containing anionic lipids and preferentially accumulates into liquid disordered (Ld) domains. Furthermore, we show that binding of oligomers to the membrane and disruption of the membrane require different lipid properties. Thus membrane-bound oligomeric alphaS does not always cause bilayer disruption.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18930058     DOI: 10.1016/j.febslet.2008.10.009

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  17 in total

1.  Effects of curvature and composition on α-synuclein binding to lipid vesicles.

Authors:  Elizabeth R Middleton; Elizabeth Rhoades
Journal:  Biophys J       Date:  2010-10-06       Impact factor: 4.033

2.  Two different binding modes of α-synuclein to lipid vesicles depending on its aggregation state.

Authors:  Tobias Högen; Johannes Levin; Felix Schmidt; Mario Caruana; Neville Vassallo; Hans Kretzschmar; Kai Bötzel; Frits Kamp; Armin Giese
Journal:  Biophys J       Date:  2012-04-03       Impact factor: 4.033

Review 3.  Impact of membrane curvature on amyloid aggregation.

Authors:  Mayu S Terakawa; Yuxi Lin; Misaki Kinoshita; Shingo Kanemura; Dai Itoh; Toshihiko Sugiki; Masaki Okumura; Ayyalusamy Ramamoorthy; Young-Ho Lee
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-04-28       Impact factor: 3.747

Review 4.  Biophysics of α-synuclein membrane interactions.

Authors:  Candace M Pfefferkorn; Zhiping Jiang; Jennifer C Lee
Journal:  Biochim Biophys Acta       Date:  2011-07-28

Review 5.  Intrinsically disordered proteins and their environment: effects of strong denaturants, temperature, pH, counter ions, membranes, binding partners, osmolytes, and macromolecular crowding.

Authors:  Vladimir N Uversky
Journal:  Protein J       Date:  2009-10       Impact factor: 2.371

6.  Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Ghulam M Ashraf; Nigel H Greig; Taqi A Khan; Iftekhar Hassan; Shams Tabrez; Shazi Shakil; Ishfaq A Sheikh; Syed K Zaidi; Mohammad Akram; Nasimudeen R Jabir; Chelaprom K Firoz; Aabgeena Naeem; Ibrahim M Alhazza; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

Review 7.  Implications of peptide assemblies in amyloid diseases.

Authors:  Pu Chun Ke; Marc-Antonie Sani; Feng Ding; Aleksandr Kakinen; Ibrahim Javed; Frances Separovic; Thomas P Davis; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

8.  How epigallocatechin gallate can inhibit α-synuclein oligomer toxicity in vitro.

Authors:  Nikolai Lorenzen; Søren B Nielsen; Yuichi Yoshimura; Brian S Vad; Camilla Bertel Andersen; Cristine Betzer; Jørn D Kaspersen; Gunna Christiansen; Jan S Pedersen; Poul Henning Jensen; Frans A A Mulder; Daniel E Otzen
Journal:  J Biol Chem       Date:  2014-06-06       Impact factor: 5.157

9.  Low-resolution structure of a vesicle disrupting α-synuclein oligomer that accumulates during fibrillation.

Authors:  Lise Giehm; Dmitri I Svergun; Daniel E Otzen; Bente Vestergaard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-07       Impact factor: 11.205

Review 10.  α-Synuclein oligomers: an amyloid pore? Insights into mechanisms of α-synuclein oligomer-lipid interactions.

Authors:  Martin T Stöckl; Niels Zijlstra; Vinod Subramaniam
Journal:  Mol Neurobiol       Date:  2012-09-06       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.